Halozyme Therapeutics Deal History & Licensing Activity
Halozyme Therapeutics is a biotech headquartered in US. Over the past three years, Halozyme Therapeutics has been involved in 5 licensing and acquisition transactions, with a primary focus on Antibodies (5 deals). The company currently has 2 active clinical trials, primarily in Metabolic.
Deals (12mo)
4
Active Trials
2
Top Modality
Antibodies
Focus Area
Metabolic
Halozyme Therapeutics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Halozyme Therapeutics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| vedolizumab with ENHANZE | Takeda | Antibodies | Unknown | collaboration | Jun 15, 2026 |
| ORKA-001 (Hypercon technology) | Oruka Therapeutics | Other | Preclinical | collaboration | May 6, 2026 |
| Hypercon technology | Vertex Pharmaceuticals | Other | Unknown | collaboration | Apr 7, 2026 |
| nimacimab co-formulated with ENHANZE | Skye Bioscience | Antibodies | Phase 2 | collaboration | Jan 5, 2026 |
Halozyme Therapeutics Pipeline Focus
Therapeutic areas and modalities where Halozyme Therapeutics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Halozyme Therapeutics Strategic Signals
Key indicators of Halozyme Therapeutics's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Halozyme Therapeutics Clinical Pipeline
Halozyme Therapeutics has 2 active clinical trials across 2 development phases.
1
Not Applicable
1
Phase 3
See How Your Asset Matches Halozyme Therapeutics's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Metabolic assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Dermatology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for dermatology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Halozyme Therapeutics Licensing & Deal Activity
Halozyme Therapeutics is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, Halozyme Therapeutics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Halozyme Therapeutics include Metabolic (3 deals and trials), Gastroenterology (2 deals and trials), Dermatology (2 deals and trials), and Rare Disease (2 deals and trials). In terms of modality, Halozyme Therapeutics has shown particular interest in antibodies, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Halozyme Therapeutics and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Halozyme Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.